Répertoire du corps professoral

Chaire de recherche du Canada en neuroimmunologie
Programme: Chaires de recherche du Canada - Fonctionnement
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 juillet 2023 au 30 juin 2030

Chercheur d'un jour
Programme: PromoScience
Organisme(s) subventionnaire(s): Conseil de recherches en sciences naturelles et génie Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 janvier 2023 au 31 décembre 2025

Therapeutic properties of innate immune cells and system for brain diseases
Programme: Développement de la recherche (FC)
Organisme(s) subventionnaire(s): CHU de Québec – Université Laval – CHUL
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 avril 2022 au 31 mars 2025

Acquisition d’équipements pour les activités de recherche en oncologie de précision au Nouveau Complexe hospitalier
Programme: Programme de soutien aux organismes de recherche et d'innovation (PSO) - Volet 4: Soutien au financement d'infrastructures de recherche et d'innovation
Organisme(s) subventionnaire(s): CHU de Québec – Université Laval – CHUL, Ministère de l'Économie et de l'Innovation
Type de financement: Subvention
Établissement tête: Université Laval
Du 24 mars 2022 au 23 mars 2027

Financements des 2 dernières années

Chercheur d'un jour
Programme: PromoScience
Organisme(s) subventionnaire(s): Conseil de recherches en sciences naturelles et génie Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 janvier 2021 au 31 décembre 2022

Programme chercheur-e d'un jour
Programme: Subventions générales de recherche et projets spéciaux (non partageable au prorata)
Organisme(s) subventionnaire(s): Fonds de recherche du Québec - Société et culture
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 avril 2018 au 31 mars 2024

Chaire de recherche du Canada en neuroimmunologie
Programme: Chaires de recherche du Canada - Fonctionnement
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 juillet 2016 au 30 juin 2023

Développement de marqueurs génétiques de maladies rares.
Organisme(s) subventionnaire(s): Fondation du CHU de Québec
Type de financement: Subvention
Établissement tête: Université Laval
Du 11 février 2016 au 31 mars 2024

Encadrements terminés dans les 5 dernières années

Morgan McLaughlin, Maîtrise en neurosciences - avec mémoire

Majid Ghareghani, Doctorat en neurobiologie

Pierre-Alexandre Piec, Maîtrise en médecine moléculaire - avec mémoire

Vincent Pons, Doctorat en médecine moléculaire

Laura Martínez Drudis, Doctorat en médecine moléculaire

Adham Fani Maleki, Doctorat en médecine moléculaire

Publications des 5 dernières années

Targeting Systemic Innate Immune Cells as a Therapeutic Avenue for Alzheimer Disease Pharmacological reviews, 2022. DOI 10.1124/pharmrev.121.000400

Structural analysis of the microglia-interneuron interactions in the CA1 hippocampal area of the APP/PS1 mouse model of Alzheimer's disease The Journal of comparative neurology, 2022. DOI 10.1002/cne.25289

Reduced Melatonin Levels May Facilitate Glioblastoma Initiation in the Subventricular Zone Expert reviews in molecular medicine, 2022. DOI 10.1017/erm.2022.15

PRMT1 is required for the generation of MHC-associated microglia and remyelination in the central nervous system Life science alliance, 2022. DOI 10.26508/lsa.202201467

PDK4 Inhibition Ameliorates Melatonin Therapy by Modulating Cerebral Metabolism and Remyelination in an EAE Demyelinating Mouse Model of Multiple Sclerosis Frontiers in immunology, 2022. DOI 10.3389/fimmu.2022.862316

Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression Brain, behavior, and immunity, 2022. DOI 10.1016/j.bbi.2021.07.016

Context-dependent transcriptional regulation of microglial proliferation Glia, 2022. DOI 10.1002/glia.24124

Case Report: Two Families With HPDL Related Neurodegeneration Frontiers in genetics, 2022. DOI 10.3389/fgene.2022.780764

Triggering Innate Immune Receptors as New Therapies in Alzheimer's Disease and Multiple Sclerosis Cells, 2021. DOI 10.3390/cells10082164

The Intellicage system provides a reproducible and standardized method to assess behavioral changes in cuprizone-induced demyelination mouse model Behavioural brain research, 2021. DOI 10.1016/j.bbr.2020.113039

Targeting innate immunity to protect and cure Alzheimer's disease: opportunities and pitfalls Molecular psychiatry, 2021. DOI 10.1038/s41380-021-01083-4

Selective Immunomodulatory and Neuroprotective Effects of a NOD2 Receptor Agonist on Mouse Models of Multiple Sclerosis Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2021. DOI 10.1007/s13311-020-00998-0

Multifocal Cerebral Microinfarcts Modulate Early Alzheimer's Disease Pathology in a Sex-Dependent Manner Frontiers in immunology, 2021. DOI 10.3389/fimmu.2021.813536

Correction to: Selective Immunomodulatory and Neuroprotective Effects of a NOD2 Receptor Agonist on Mouse Models of Multiple Sclerosis Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2021. DOI 10.1007/s13311-021-01035-4

Conditional genetic deletion of CSF1 receptor in microglia ameliorates the physiopathology of Alzheimer's disease Alzheimer's research & therapy, 2021. DOI 10.1186/s13195-020-00747-7

A founder mutation in the gene in families from Saguenay-Lac-St-Jean region affected by a pyridoxine-dependent epilepsy JIMD reports, 2021. DOI 10.1002/jmd2.12196

A Homozygous Deep Intronic Mutation Alters the Splicing of Nebulin Gene in a Patient With Nemaline Myopathy Frontiers in neurology, 2021. DOI 10.3389/fneur.2021.660113

Whole-exome sequencing identifies homozygous mutation in TTI2 in a child with primary microcephaly: a case report BMC neurology, 2020. DOI 10.1186/s12883-020-01643-1

Role of Macrophage Colony-Stimulating Factor Receptor on the Proliferation and Survival of Microglia Following Systemic Nerve and Cuprizone-Induced Injuries Frontiers in immunology, 2020. DOI 10.3389/fimmu.2020.00047

QUAKING Regulates Microexon Alternative Splicing of the Rho GTPase Pathway and Controls Microglia Homeostasis Cell reports, 2020. DOI 10.1016/j.celrep.2020.108560

Muramyl dipeptide-mediated immunomodulation on monocyte subsets exerts therapeutic effects in a mouse model of Alzheimer's disease Journal of neuroinflammation, 2020. DOI 10.1186/s12974-020-01893-3

Microglia Purinoceptor P2Y6: An Emerging Therapeutic Target in CNS Diseases Cells, 2020. DOI 10.3390/cells9071595

Inflammatory Monocytes and Neutrophils Regulate Streptococcus suis-Induced Systemic Inflammation and Disease but Are Not Critical for the Development of Central Nervous System Disease in a Mouse Model of Infection Infection and immunity, 2020. DOI 10.1128/IAI.00787-19

Beneficial Roles of Microglia and Growth Factors in MS, a Brief Review Frontiers in cellular neuroscience, 2020. DOI 10.3389/fncel.2020.00284

An Early Microglial Response Is Needed To Efficiently Control Herpes Simplex Virus Encephalitis Journal of virology, 2020. DOI 10.1128/JVI.01428-20

Alzheimer's disease: microglia targets and their modulation to promote amyloid phagocytosis and mitigate neuroinflammation Expert opinion on therapeutic targets, 2020. DOI 10.1080/14728222.2020.1738391

Ultrastructural evidence of microglial heterogeneity in Alzheimer's disease amyloid pathology Journal of neuroinflammation, 2019. DOI 10.1186/s12974-019-1473-9

Innate Immune Cells: Monocytes, Monocyte-Derived Macrophages and Microglia as Therapeutic Targets for Alzheimer's Disease and Multiple Sclerosis Frontiers in cellular neuroscience, 2019. DOI 10.3389/fncel.2019.00355